Defendant
3 cases as defendant.
BioMarin Pharmaceutical Inc., commonly known as BioMarin, is a global biotechnology company headquartered in San Rafael, California. Founded in March 1997 by Christopher Starr, Ph.D., and Grant W. Denison Jr., it operates as a publicly held entity, trading on Nasdaq under the ticker symbol BMRN. As of late 2025/early 2026, BioMarin employs approximately 3,221 individuals and reported a trailing twelve-month revenue of around $3.24 billion, with a market capitalization of approximately $10.3 billion to $10.5 billion.
The company focuses on developing and commercializing innovative therapies for patients with serious and life-threatening rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, small molecules, and other advanced treatments. Its portfolio includes eight approved therapies addressing conditions such as achondroplasia, phenylketonuria (PKU), hemophilia A, and mucopolysaccharidosis (MPS). Key commercial products include Vimizim, Naglazyme, Palynziq, Brineura, Aldurazyme, Roctavian, Kuvan, Voxzogo, Galafold, and Pombiliti + Opfolda.
BioMarin Pharmaceutical Inc. exhibits an active patent litigation posture, appearing in three tracked cases. The company has acted as a plaintiff in two cases, both filed in the District of New Jersey: BioMarin Pharmaceutical Inc. v. Zydus Lifesciences Ltd and BioMarin Pharmaceutical Inc. v. Unknown Defendant. Conversely, BioMarin has been a defendant in one case, Unified Patents v. Biomarin Pharmaceutical Inc., before the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO).
This litigation profile indicates that BioMarin is an operating company actively defending its intellectual property and asserting its patent rights, likely against generic competitors given the nature of the pharmaceutical industry. The suit brought by Unified Patents, an organization known for challenging patents, further underscores BioMarin's status as a significant patent holder in its specialized biotechnology field.
Ascendis Pharma A/S filed a declaratory judgment action against BioMarin; the docket listed U.S. Patents 8,198,242, 8,906,847, and RE48,267. The district court granted BioMarin's motion for a discretionary stay on September 19, 2025, and denied Ascendis's mandatory stay motion as moot; the case was later resolved by the August 2026 global settlement.
Ascendis entities filed a declaratory judgment action of non-infringement against BioMarin, also invoking the 35 U.S.C. § 271(e)(1) safe harbor. Ascendis voluntarily dismissed without prejudice on July 7, 2025, stating it would refile to seek a mandatory stay under 28 U.S.C. § 1659(a)(2).
Declaratory-judgment/safe-harbor action by Ascendis Pharma A/S against BioMarin involving §271(e)(1) and a forum dispute with the parallel ITC action. US 8,377,884 was cited in BioMarin's filings as Exhibit 32 in connection with Ascendis's ITC prior-art/protest arguments concerning RE'267, not as an asserted patent. Resolved by the August 30, 2026 global settlement.